Pfizer and Samsung Biologics agree $411 Million biosimilar manufacturing partnership

Samsung Biologics has entered into a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio.

Under the new deal, valued at $411 Million, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio.

This partnership is a significant step forward for both companies in the rapidly growing biosimilars market.

• Samsung Biologics will provide additional capacity for large-scale manufacturing
• The partnership is for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio
• The deal is a significant step forward for both companies in the rapidly growing biosimilars market